I agree. But their whole business model is about having the IP rights for small to very large chemical entities, then supplying manufacturing, marketing, regulatory, and distribution expertise.

To get outside this box could threaten their whole business model of supplying rough equivalents of "magic bullets" to fight disease. And it's not just them, it's Wall Street, and it's even people like you and I, who probably own their stock in some fund or another, as part of our retirement savings. Systemic.